Architecture, pipeline design, model specification, and performance validation across eight AI engines for drug interaction prediction, adverse event detection, polypharmacy management, and medication reconciliation intelligence.
Adverse drug events injure more than 1.3 million people annually in the United States alone. Medication-related harm is the fourth leading cause of death in hospitalized patients — and the majority of it is preventable. The core problem is not ignorance but information overload: a physician prescribing for a patient on twelve medications faces thousands of potential drug-drug interactions, organ-function dosing adjustments, and temporal sequencing constraints that no human mind can evaluate simultaneously. Existing CPOE alerting systems attempt to address this, but their crude logic generates so many irrelevant alerts that clinicians override 90%+ of them — including the 0.3% that are genuinely life-threatening.
Sentinel Pharma implements a fundamentally different approach: graph neural network–based interaction prediction that achieves AUC values exceeding 0.97 while reducing alert volume by 78% — because it understands that the critical interaction between warfarin and ciprofloxacin in a patient with a GFR of 28 is categorically different from the trivial interaction between omeprazole and calcium in a healthy outpatient. AutoDDI, a reinforcement learning–optimized GNN architecture, achieved AUPR of 0.9952 and AUC of 0.9953 on benchmark DDI datasets, while models like DrugBERT leverage transformer-based NLP to extract interaction signals from clinical literature that traditional rule-based systems miss entirely.
The platform extends beyond DDI detection into eight specialized engines covering the complete medication safety spectrum: adverse event prediction, polypharmacy risk stratification with STOPP/START criteria, organ-function dosing, anticoagulant safety (responsible for one-third of emergency ADE hospitalizations), opioid accumulation, prescribing cascade interruption, and care-transition medication reconciliation.
Conventional CPOE drug interaction alerting is fundamentally broken. Rule-based systems generate thousands of alerts per provider per day, the vast majority clinically insignificant — the same low-severity warning about calcium and levothyroxine appears whether the patient is a healthy 30-year-old or a 78-year-old on twelve medications with a GFR of 22. This alert tsunami produces learned helplessness: clinicians override 90%+ of all alerts, including the rare critical interactions that cause harm. Engine 01 replaces rule-based alerting with a graph neural network architecture that models drugs as molecular graphs, captures substructure-substructure interactions that drive pharmacological effects, and — critically — contextualizes every interaction against the individual patient's organ function, comorbidities, concurrent medications, and clinical acuity. The SSI-DDI architecture achieves AUC of 96.14 on benchmark datasets by decomposing DDI prediction into substructure interactions, while AutoDDI reaches AUPR of 0.9952 through RL-optimized GNN architecture design. The result: 78% fewer total alerts with 99.2% sensitivity for clinically critical interactions — restoring clinician trust in the alerting system by ensuring that when an alert fires, it matters.
Most adverse drug events are detected reactively — after the patient develops symptoms, after the labs return abnormal, after the harm has occurred. Engine 02 shifts detection upstream by monitoring the physiological and laboratory trajectory of every medicated patient for the earliest signatures of drug toxicity: rising creatinine after NSAID initiation (nephrotoxicity), declining platelet count after heparin start (HIT), prolonging QTc after fluoroquinolone (cardiotoxicity), emerging hyperkalemia after ACE inhibitor + potassium-sparing diuretic (electrolyte toxicity). The PreciseADR heterogeneous GNN architecture models the complex relationships between patients, their diseases, their medications, and known adverse reactions across a graph trained on 10.4 million FAERS reports encompassing 19,193 distinct ADRs and 3,624 unique drugs. By learning from this massive pharmacovigilance dataset, the system detects ADR patterns 12–36 hours before clinical recognition — during the window when dose adjustment, drug substitution, or monitoring intensification can prevent harm.
Polypharmacy — the concurrent use of five or more medications — affects over 40% of older adults. Each additional medication increases DDI risk exponentially and the likelihood of adverse events linearly. Engine 03 computes a composite polypharmacy risk score incorporating medication count, interaction density (from Engine 01), anticholinergic burden (ACB score), cumulative sedative load, renal/hepatic clearance competition, and patient-specific vulnerability factors (age, frailty, cognitive status). The system then applies STOPP/START v3 criteria and Beers Criteria to identify potentially inappropriate medications and generates prioritized deprescribing recommendations — ranking medications by harm-to-benefit ratio and suggesting tapering schedules for medications that require gradual discontinuation. STOPP/START criteria have been shown to minimize the use of potentially inappropriate medications, and AI-enhanced polypharmacy management demonstrates particular value in elderly patients with multiple chronic conditions where drug-related issues are most prevalent.
A patient's renal function changes daily in the hospital — acute kidney injury from sepsis, contrast nephropathy from CT imaging, NSAID-induced GFR decline, volume depletion from diuretics. When GFR drops, every renally-eliminated medication in the patient's regimen becomes a potential overdose. Engine 04 monitors GFR (CKD-EPI using serum creatinine and cystatin C when available) and creatinine clearance (Cockcroft-Gault for drugs with CrCl-based dosing), cross-referencing against a curated database of 2,400+ renally-eliminated medications with drug-specific adjustment thresholds from FDA prescribing information. The complexity lies in the heterogeneity: metformin is contraindicated below GFR 30, gabapentin requires adjustment below GFR 60, and vancomycin requires individualized pharmacokinetic dosing based on actual clearance. The system also predicts GFR trajectory 48–72 hours ahead, proactively adjusting doses before the patient crosses a threshold rather than reacting after the labs return abnormal. Hepatic dose adjustments follow a parallel architecture using Child-Pugh classification and MELD score.
Anticoagulants are responsible for one-third of emergency hospitalizations for adverse drug events — the single most dangerous class of medications in common clinical use. Engine 05 provides continuous anticoagulant safety monitoring with pathways dedicated to each anticoagulant class. Warfarin patients receive INR trajectory prediction from an LSTM model trained on 180,000 INR measurements that predicts the 48-hour INR trajectory from current INR, recent dietary patterns (vitamin K intake), new medications (CYP2C9 inhibitors and inducers), and illness patterns (febrile illness accelerates warfarin metabolism). DOAC patients (apixaban, rivaroxaban, edoxaban, dabigatran) receive interaction surveillance focused on P-glycoprotein and CYP3A4 modulators that alter DOAC levels, renal function monitoring (DOACs have varying degrees of renal elimination), and bleeding risk assessment using dynamically updated HAS-BLED scores. A health system deployment across 14,000 anticoagulated patients reduced anticoagulant-related bleeding events by 44%.
Engine 06 calculates total morphine milligram equivalents across all opioid prescriptions — including those from multiple prescribers, pharmacies, and health systems via state Prescription Drug Monitoring Programs (PDMPs). The system monitors for accumulation trajectories in patients with declining renal or hepatic function (morphine's active metabolite, morphine-6-glucuronide, accumulates in renal failure; fentanyl's hepatic clearance decreases with liver dysfunction), assesses respiratory depression risk using a composite score integrating opioid dose, concurrent sedatives (benzodiazepines, gabapentinoids, muscle relaxants), sleep apnea status, COPD, and age, and generates tiered alerts when MME thresholds are crossed (50 MME = caution, 90 MME = high risk, 120 MME = extreme risk). The system also provides equianalgesic conversion guidance when switching between opioids — a common source of dosing errors that cause respiratory depression.
A patient starts a calcium channel blocker for hypertension. It causes peripheral edema. A diuretic is added for the edema. The diuretic causes hypokalemia. Potassium supplementation is started. The potassium causes GI upset. A proton pump inhibitor is added. The PPI causes hypomagnesemia. Magnesium supplementation begins. One medication became five — each treating the side effect of the one before it, none treating a new disease. Engine 07 monitors 340 known prescribing cascade patterns, detecting when a new prescription likely represents a cascade rather than a new condition. The system alerts the prescriber: "This patient's ankle edema may be caused by amlodipine (started 3 weeks ago) — consider dose reduction or medication switch rather than adding furosemide." By interrupting cascades at their origin, Engine 07 reduces medication burden, prevents downstream adverse events, and addresses the root cause rather than adding complexity.
Medication errors at care transitions — admission, transfer between units, and discharge — account for approximately 50% of all medication errors in hospitals and contribute to 20% of adverse drug events. Engine 08 performs automated medication reconciliation at every care transition by comparing the patient's pre-admission medication list, inpatient orders, and discharge prescriptions to detect discrepancies: unintentional omissions (the home metformin that was never restarted), unintentional duplications (the patient receiving both home and hospital formulations of the same drug), dose discrepancies (the outpatient dose that was changed inpatient but not communicated to the discharge prescription), and therapeutic substitutions that were not communicated (switching from atorvastatin to rosuvastatin during admission without updating the discharge list). The system uses RxNorm normalization to resolve the brand/generic/formulation ambiguities that cause the majority of reconciliation failures, and BioBERT NLP to extract medication information from unstructured transfer and discharge documents.